Meeting
2011 ASCO Annual Meeting
Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.
Authors
M. Talpaz
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
M. Talpaz , N. P. Shah , M. W. Deininger , M. J. Mauro , I. W. Flinn , S. Lustgarten , W. Lindmark , J. M. Gozgit , T. Clackson , C. D. Turner , F. G. Haluska , H. Kantarjian , J. E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00660920
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6518)
Abstract #
6518
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
First Author: Benjamin J. Solomon
Poster
2016 ASCO Annual Meeting
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
First Author: Maro Ohanian
Poster
2014 ASCO Annual Meeting
Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.
First Author: Moshe Talpaz
First Author: Rüdiger Hehlmann